Movement Alert｜Akeso Rises 4.39% in Regular Trading, Novel Bispecific ADC Completes First Patient Dosing in Phase II NSCLC Study

Market Focus07-22

On July 22, Akeso rose 4.39% in regular trading, trading at HK$100.8/share, with turnover of HK$258 million.

On the news front, Akeso recently announced that its novel Trop2/Nectin-4 bispecific antibody-drug conjugate (AK146D1) in combination with ivonescimab (PD-1/VEGF bispecific antibody) has completed first patient dosing in a Phase II clinical study for advanced non-small cell lung cancer. The study aims to evaluate safety and preliminary efficacy, particularly in the first-line NSCLC setting. This milestone marks the companys IO2.0+ADC2.0 dual-platform strategy entering a critical advancement stage, with multiple next-generation ADC candidates now in Phase II development.

The broader biotechnology sector also provided support, with Remegen up 4.46%, 3SBio up 4.20%, Innovent Bio up 2.12%, and BeiGene up 1.97%. Multiple brokerages have recently maintained buy ratings on Akeso, with CITIC Construction noting the companys globally competitive Tetrabody bispecific antibody technology platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128741716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128741716","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Rises 4.39% in Regular Trading, Novel Bispecific ADC Completes First Patient Dosing in Phase II NSCLC Study","media":"Market Focus","content":"<p><p>On July 22, Akeso rose 4.39% in regular trading, trading at HK$100.8/share, with turnover of HK$258 million.</p><p>On the news front, Akeso recently announced that its novel Trop2/Nectin-4 bispecific antibody-drug conjugate (AK146D1) in combination with ivonescimab (PD-1/VEGF bispecific antibody) has completed first patient dosing in a Phase II clinical study for advanced non-small cell lung cancer. The study aims to evaluate safety and preliminary efficacy, particularly in the first-line NSCLC setting. This milestone marks the companys IO2.0+ADC2.0 dual-platform strategy entering a critical advancement stage, with multiple next-generation ADC candidates now in Phase II development.</p><p>The broader biotechnology sector also provided support, with Remegen up 4.46%, 3SBio up 4.20%, Innovent Bio up 2.12%, and BeiGene up 1.97%. Multiple brokerages have recently maintained buy ratings on Akeso, with CITIC Construction noting the companys globally competitive Tetrabody bispecific antibody technology platform.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Rises 4.39% in Regular Trading, Novel Bispecific ADC Completes First Patient Dosing in Phase II NSCLC Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Rises 4.39% in Regular Trading, Novel Bispecific ADC Completes First Patient Dosing in Phase II NSCLC Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-22 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 22, Akeso rose 4.39% in regular trading, trading at HK$100.8/share, with turnover of HK$258 million.</p><p>On the news front, Akeso recently announced that its novel Trop2/Nectin-4 bispecific antibody-drug conjugate (AK146D1) in combination with ivonescimab (PD-1/VEGF bispecific antibody) has completed first patient dosing in a Phase II clinical study for advanced non-small cell lung cancer. The study aims to evaluate safety and preliminary efficacy, particularly in the first-line NSCLC setting. This milestone marks the companys IO2.0+ADC2.0 dual-platform strategy entering a critical advancement stage, with multiple next-generation ADC candidates now in Phase II development.</p><p>The broader biotechnology sector also provided support, with Remegen up 4.46%, 3SBio up 4.20%, Innovent Bio up 2.12%, and BeiGene up 1.97%. Multiple brokerages have recently maintained buy ratings on Akeso, with CITIC Construction noting the companys globally competitive Tetrabody bispecific antibody technology platform.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1128741716","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128741716","pubTimestamp":1784684601,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 22, Akeso rose 4.39% in regular trading, trading at HK$100.8/share, with turnover of HK$258 million.On the news front, Akeso recently announced that its novel Trop2/Nectin-4 bispecific...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动态警报|Akeso常规交易涨4.39%，新型双特异性ADC完成II期非小细胞肺癌研究首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 22, Akeso rose 4.39% in regular trading, trading at HK$100.8/share, with turnover of HK$258 million.On the news front, Akeso recently announced that its novel Trop2/Nectin-4 bispecific antibody-drug conjugate (AK146D1) in combination with ivonescimab (PD-1/VEGF bispecific antibody) has completed first patient dosing in a Phase II clinical study for advanced non-small cell lung cancer. The study aims to evaluate safety and preliminary efficacy, particularly in the first-line NSCLC setting. This milestone marks the companys IO2.0+ADC2.0 dual-platform strategy entering a critical advancement stage, with multiple next-generation ADC candidates now in Phase II development.The broader biotechnology sector also provided support, with Remegen up 4.46%, 3SBio up 4.20%, Innovent Bio up 2.12%, and BeiGene up 1.97%. Multiple brokerages have recently maintained buy ratings on Akeso, with CITIC Construction noting the companys globally competitive Tetrabody bispecific antibody technology platform.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128741716","isCrawlerRequest":true}